AbbVie has reported global net revenues of $12.23bn for the first quarter (Q1) of 2023, representing a decline of 9.7% on a reported basis and 8.3% on an operational basis from Q1 2022.

During Q1 2023, net revenues from the company’s immunology portfolio fell to $5.59bn, down by 9% on a reported basis and 7.8% on an operational basis.

Global net revenues from the drug Humira were $3.54bn, a 25.2% decline on a reported basis, or 24.3% on an operational basis, from the same quarter of the previous year.

The drug generated net revenues of $2.95bn in the US, a drop of 26.1% year-on-year.

AbbVie has reported global net revenues of $1.36bn from Skyrizi and $686m from Rinvoq. The net revenue growth on a reported basis was 44.7% for Skyrizi and 47.5% for Rinvoq.

The haematologic oncology portfolio delivered $1.42bn in global net revenues during the quarter, down by 14% year-on-year on a reported basis.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company’s neuroscience portfolio witnessed a growth of 13.9% on a reported basis over Q1 2022, registering net revenues of $1.7bn.   

Net revenues from the aesthetics portfolio fell by 5.4% to $1.3bn, compared to the same period last year.

AbbVie chairman and CEO Richard Gonzalez stated: “This year is off to an excellent start, with first-quarter revenues and EPS ahead of our expectations, driven by strong commercial execution across all areas of our diversified portfolio.

“These balanced results give us confidence to increase our full-year guidance and we see numerous opportunities for key assets to drive compelling long-term growth.”

For the full year 2023, the company has increased its adjusted diluted earnings per share (EPS) guidance range from between $10.62 and $11.02 to between $10.72 and $11.12.